In the new parallel phase I cohort, the intraperitoneal delivery of Mcy-M11 will be assessed at escalating doses in additional patients with relapsed/refractory ovarian cancer and malignant peritoneal mesothelioma. A preconditioning regimen of cyclophosphamide will be added prior to Mcy-M11 infusion in this cohort, which will progress independently from the ongoing evaluation in the existing cohort that is not receiving a preconditioning regimen.

The company noted that the phase I trial will also allow, where indicated, for multiple treatment cycles in both future preconditioning and no-preconditioning patients.

In addition, Massachusetts General Hospital and Hackensack University Medical Center have now joined existing trial sites at the U.S. National Cancer Institute and Washington University at St. Louis. Preliminary clinical data is expected from the trial in the second half of this year.

Novocellbio's COVID-19 cell therapy shows promising results
Novocellbio has confirmed that its autologous natural killer cell treatment agent is effective in killing SARS-CoV-2.

Transarterial chemoperfusion shows promise in mesothelioma patients
According to research presented during a recent virtual session of the Society of Interventional Radiology, there has been progress on a novel treatment...

Next-generation sequencing reveals inherited mutations in young cancer patients
Researchers advocated for increased genomic surveillance in younger adult cancer patients with tumors that typically strike later in life, in a study...

New consortium formed to develop cell-based cancer vaccines
A new consortium has been formed to increase access to cell-based cancer vaccines by using single-use technology to develop and manufacture dendritic...